Cargando…

Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary

AIM: The objective of this observational study was to assess the status of glycemic control and associated patient-reported outcomes in ambulatory Hungarian patients with type 2 diabetes mellitus (T2DM) who were prescribed either a sulfonylurea (SU) or a thiazolidinedione (TZD) in addition to the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Jermendy, György, Erdesz, Diana, Nagy, Laszlo, Yin, Don, Phatak, Hemant, Karve, Sudeep, Engel, Samuel, Balkrishnan, Rajesh
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600631/
https://www.ncbi.nlm.nih.gov/pubmed/18976457
http://dx.doi.org/10.1186/1477-7525-6-88
_version_ 1782162187580604416
author Jermendy, György
Erdesz, Diana
Nagy, Laszlo
Yin, Don
Phatak, Hemant
Karve, Sudeep
Engel, Samuel
Balkrishnan, Rajesh
author_facet Jermendy, György
Erdesz, Diana
Nagy, Laszlo
Yin, Don
Phatak, Hemant
Karve, Sudeep
Engel, Samuel
Balkrishnan, Rajesh
author_sort Jermendy, György
collection PubMed
description AIM: The objective of this observational study was to assess the status of glycemic control and associated patient-reported outcomes in ambulatory Hungarian patients with type 2 diabetes mellitus (T2DM) who were prescribed either a sulfonylurea (SU) or a thiazolidinedione (TZD) in addition to the prior metformin (MF) monotherapy. METHODS: Type 2 diabetics aged ≥ 30 years and who had added an SU or TZD to previous MF monotherapy at least 1 year prior to the visit date were identified during January 2006 to March 2007. Information on HbA1c (A1C), medication use and co-morbid conditions was extracted from the medical record up to 6 months prior to the addition of SU or TZD to MF (baseline), and a minimum of one year after the initiation of either SU or TZD. Glycemic control (A1C < 6.5%) was assessed using the last available A1C value in the medical record. Self-reported hypoglycemia, health-related quality of life (HRQoL) and treatment satisfaction were also assessed. RESULTS: A total of 414 patients (82% SU+MF and 18% TZD+MF) with a mean age of 60.5 years (SD = 9.4 years) participated in the study. About 27% of patients reported hypoglycemic episodes, with about one-third reporting episodes that resulted into interruption of activities or required medical/non-medical assistance. Three quarters of patients were not at glycemic goal and BMI was the only factor significantly associated with failure to have an A1C level < 6.5%. Patients' HRQoL was significantly associated with self-reported hypoglycemic episodes (p = 0.017), and duration of diabetes (p = 0.045). CONCLUSION: Nearly 75% of patients were not at A1C goal of < 6.5% despite using two oral anti-hyperglycemic medications. Approximately 9% of patients reporting hypoglycemia required some kind of medical/non-medical assistance. Greater BMI at baseline was associated with an A1C level ≥ 6.5%. Finally, self- reports of hypoglycemia and duration of diabetes were associated with low HRQoL.
format Text
id pubmed-2600631
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26006312008-12-12 Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary Jermendy, György Erdesz, Diana Nagy, Laszlo Yin, Don Phatak, Hemant Karve, Sudeep Engel, Samuel Balkrishnan, Rajesh Health Qual Life Outcomes Research AIM: The objective of this observational study was to assess the status of glycemic control and associated patient-reported outcomes in ambulatory Hungarian patients with type 2 diabetes mellitus (T2DM) who were prescribed either a sulfonylurea (SU) or a thiazolidinedione (TZD) in addition to the prior metformin (MF) monotherapy. METHODS: Type 2 diabetics aged ≥ 30 years and who had added an SU or TZD to previous MF monotherapy at least 1 year prior to the visit date were identified during January 2006 to March 2007. Information on HbA1c (A1C), medication use and co-morbid conditions was extracted from the medical record up to 6 months prior to the addition of SU or TZD to MF (baseline), and a minimum of one year after the initiation of either SU or TZD. Glycemic control (A1C < 6.5%) was assessed using the last available A1C value in the medical record. Self-reported hypoglycemia, health-related quality of life (HRQoL) and treatment satisfaction were also assessed. RESULTS: A total of 414 patients (82% SU+MF and 18% TZD+MF) with a mean age of 60.5 years (SD = 9.4 years) participated in the study. About 27% of patients reported hypoglycemic episodes, with about one-third reporting episodes that resulted into interruption of activities or required medical/non-medical assistance. Three quarters of patients were not at glycemic goal and BMI was the only factor significantly associated with failure to have an A1C level < 6.5%. Patients' HRQoL was significantly associated with self-reported hypoglycemic episodes (p = 0.017), and duration of diabetes (p = 0.045). CONCLUSION: Nearly 75% of patients were not at A1C goal of < 6.5% despite using two oral anti-hyperglycemic medications. Approximately 9% of patients reporting hypoglycemia required some kind of medical/non-medical assistance. Greater BMI at baseline was associated with an A1C level ≥ 6.5%. Finally, self- reports of hypoglycemia and duration of diabetes were associated with low HRQoL. BioMed Central 2008-10-31 /pmc/articles/PMC2600631/ /pubmed/18976457 http://dx.doi.org/10.1186/1477-7525-6-88 Text en Copyright © 2008 Jermendy et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Jermendy, György
Erdesz, Diana
Nagy, Laszlo
Yin, Don
Phatak, Hemant
Karve, Sudeep
Engel, Samuel
Balkrishnan, Rajesh
Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
title Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
title_full Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
title_fullStr Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
title_full_unstemmed Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
title_short Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
title_sort outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in hungary
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600631/
https://www.ncbi.nlm.nih.gov/pubmed/18976457
http://dx.doi.org/10.1186/1477-7525-6-88
work_keys_str_mv AT jermendygyorgy outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary
AT outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary
AT erdeszdiana outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary
AT nagylaszlo outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary
AT yindon outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary
AT phatakhemant outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary
AT karvesudeep outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary
AT engelsamuel outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary
AT balkrishnanrajesh outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary